Introduction {#Sec1}
============

Mitochondria are double membrane-bound organelles that do not only constitute the 'cellular power plants' but also are crucially involved in survival, apoptosis, redox control, Ca^2+^ homeostasis, and many metabolic and biosynthetic pathways \[[@CR1]\]. To fulfill these diverse functions, mitochondria require a highly negative membrane potential across their inner membrane (∆*ψ*), which is maintained by the action of the three proton pumps (complexes I, III, and IV) of the electron transport chain. Together with F~0~/F~1~-ATP-synthase (complex V), which uses the resulting electrochemical proton gradient to generate ATP, and complex II of the electron transport chain, which oxidizes FADH~2~, these proton pumps constitute part of the oxidative phosphorylation (OXPHOS) system, which accounts for the majority of cellular ATP production.

Complex I (EC 1.6.5.3) is the largest OXPHOS complex and clinical presentations associated with its deficiency (MIM 252010) are heterogeneous ranging from severe multi-system diseases with neonatal death (e.g., Leigh Disease) to isolated myopathies \[[@CR2]\]. Complex I consists of seven subunits encoded by the mitochondrial DNA and 38 by that of the nucleus \[[@CR3]\]. As to the nuclear genome, disease-causing mutations have been identified in the genes of core subunits NDUFV1, NDUFV2, NDUFS1, NDUFS2, NDUFS3, NDUFS7, and NDUFS8 \[[@CR4]--[@CR9]\], supernumerary subunits NDUFS4, NDUFS6, NDUFA11, and NDUFA2 \[[@CR10]--[@CR13]\], and complex I assembly factors NDUFAF2, NDUFAF1, and C6orf66 \[[@CR14]--[@CR16]\].

Detailed knowledge of the cytopathological consequences of complex I deficiency is prerequisite to understanding the clinical presentations and their heterogeneity, and developing therapeutic strategies \[[@CR17]\]. To gain this knowledge, we study skin fibroblasts from patients with mutations in nuclear complex I genes. We demonstrated that these mutations can be associated with a reduction in Ca^2+^ content of the endoplasmic reticulum (ER~Ca~; \[[@CR18], [@CR19]\]). Because OXPHOS depends on the electrochemical proton gradient, the latter might be altered in patient cells, leading to a reduced supply of ATP to ER Ca^2+^-pumps, thus explaining the observed reduction in resting ER~Ca~. In agreement with this idea, we showed before that chronic inhibition of complex I by rotenone reduced ∆*ψ* and decreased ER~Ca~ in healthy fibroblasts \[[@CR20]\]. We furthermore showed that a reduction in ER~Ca~ was paralleled by decreased amplitudes of the bradykinin (Bk)-induced increases in \[Ca^2+^\]~C~, \[Ca^2+^\]~M~, \[ATP\]~C~ and \[ATP\]~M~ \[[@CR19]\]. Finally, we demonstrated that these aberrations were accompanied by a decrease in the rate of cytosolic Ca^2+^ removal during the decay phase of the Bk-induced \[Ca^2+^\]~C~ transient \[[@CR19]\]. Because Bk stimulates the release of Ca^2+^ from the ER into the cytosol from which Ca^2+^ is taken up by mitochondria to stimulate the OXPHOS process, these data suggest that the reduction in resting ER~Ca~ is responsible for the decrease in Bk-stimulated mitochondrial ATP production, which, in turn, results in a lower cytosolic Ca^2+^ removal rate. Evidence comes from experiments with, on the one hand, an inhibitor of mitochondrial Na^+^--Ca^2+^ exchange, which was shown to normalize both the Bk-induced increase in \[ATP\]~M~ and the rate of cytosolic Ca^2+^ removal in patient fibroblasts \[[@CR18]\], and on the other hand a mitochondrial Ca^2+^ buffer, which decreased both parameters in fibroblasts of a healthy individual \[[@CR21]\].

Apart from alterations in intracellular Ca^2+^ handling we observed elevated levels of reactive oxygen species (ROS) in fibroblasts of patients with a nuclear complex I gene defect \[[@CR22], [@CR23]\]. Because elevated ROS levels have been associated with a less negative ∆*ψ* \[[@CR24], [@CR25]\], and because a less negative ∆*ψ* might decrease mitochondrial ATP-dependent Ca^2+^ uptake by the ER (see above), we here investigated the relationship between ∆*ψ*, elevated ROS levels and ER~Ca~ in these patient fibroblasts.

Materials and methods {#Sec2}
=====================

Cell lines {#Sec3}
----------

Fibroblasts were obtained following informed parental consent and according to the relevant Institutional Review Boards from skin biopsies of four healthy subjects and ten patients in whom an isolated complex I deficiency was confirmed in both muscle tissue and cultured fibroblasts (Table [1](#Tab1){ref-type="table"}). Activity measurements were performed as described previously \[[@CR26]\]. The activity of the complex was normalized against that of cytochrome *c* oxidase, which was in the control range, and expressed as percentage of the lowest control (0.11 mU/mU cytochrome *c* oxidase; \[[@CR26]\]). All patients were negative with respect to mitochondrial DNA alterations previously associated with complex I deficiency. Fibroblasts were cultured in HEPES (25 mM)-buffered M199 medium (Invitrogen) supplemented with 10% (*v*/*v*) fetal calf serum, 5 mg/l Tween 20, 100 IU/ml penicillin and 100 IU/ml streptomycin. Table 1Characteristics of control and patient fibroblastsCell line^a^MutationCI act.^b^Mean TMRM pixel intensity^c^ER Ca^2+^ content^d^Rate of CM-DCF formation^e^GeneProteinC-5120NoneNone113100 ± 0.2 (*N* = 1033)100 ± 1 (*N* = 81)100 ± 2 (*N* = 412)C-4996NoneNoneN.d.100 ± 0.7 (*N* = 134)N.d.N.d.C-5118NoneNone10399 ± 0.7 (*N* = 115)102 ± 8 (*N* = 20)125 ± 13 (*N* = 61)C-5119NoneNone10599 ± 1.1 (*N* = 65)102 ± 6 (*N* = 15)100 ± 11 (*N* = 48)S1-6173*NDUFS1*R557X/D618N31*92* ± *0.8* (*N* = 120)*82* ± *4* (*N* = 29)*171* ± *13 (N* = *87)*S2-5067*NDUFS2*P229Q36*94* ± *1.2* (N = 105)94 ± 4 (*N* = 70)*351* ± *41* (*N* = 28)S2-5170*NDUFS2*R228Q39*99* ± *0.6* (*N* = 126)95 ± 2 (*N* = 23)*169* ± *7* (*N* = 124)S4-4608*NDUFS4*K158fs75*87* ± *0.8* (*N* = 112)96 ± 4 (*N* = 44)*289* ± *46* (*N* = 29)S4-5260*NDUFS4*R106X36*92* ± *0.9* (*N* = 110)*77* ± *4 (N* = *40)187* ± *12 (N* = *160)*S4-5737*NDUFS4*VPEEH167/VEKSIstop53*95* ± *0.6* (*N* = 160)*87* ± *6* (*N* = 22)*202* ± *12 (N* = *98)*S7-5175*NDUFS7*V122M68*91* ± *0.4* (*N* = 384)*73* ± *2* (*N* = 16)*212* ± *15 (N* = *76)*S8-6603*NDUFS8*R94C18*89* ± *0.8* (*N* = 121)*85* ± *6* (*N* = 17)*275* ± *20 (N* = *117)*V1-5866*NDUFV1*R59X/T423M64*94* ± *0.8* (*N* = 68)*87* ± *3* (*N* = 43)*135* ± *12 (N* = *49)*V1-5171*NDUFV1*R59X/T423M73*92* ± *1* (*N* = 104)96 ± 3 (*N* = 48)*242* ± *19* (*N* = 78)Statistics: values significantly different from control C-5120 (*p* \< 0.05) are depicted in italics*N* indicates the number of cells analyzed, *N.d.* not determined, *C* indicates control cells^a^Numerals indicate the designation of the cell lines within the Nijmegen Center for Mitochondrial Disorders (NCMD)^b^Determined relative to complex IV and expressed as percentage of lowest control \[[@CR35]\]^c^Expressed as % of the value for control C-5120^d^ER~Ca~, expressed as % of the value for control C-5120 \[[@CR23], [@CR25]\]^e^Expressed as % of the value for control C-5120 \[[@CR27], [@CR28]\]

Fluorescence imaging of ∆*ψ* {#Sec4}
----------------------------

∆*ψ* was measured by digital imaging microscopy of fibroblasts loaded with tetramethyl rhodamine methyl ester (TMRM) as described in detail before \[[@CR27]\]. During measurements, cells were maintained in a HEPES--Tris medium (pH 7.4) containing 132 mM NaCl, 4.2 mM KCl, 5.5 mM [d]{.smallcaps}-glucose, 1 mM MgCl~2~, 1 mM CaCl~2~ and 10 mM HEPES.

Luminescence monitoring of \[Ca^2+^\]~M~ and \[ATP\]~M~ {#Sec5}
-------------------------------------------------------

\[Ca^2+^\]~M~ and \[ATP\]~M~ were determined by luminometry of fibroblasts transduced with a baculovirus encoding mitochondrial targeted forms of wild-type aequorin (mtAEQ) and luciferase (mtLUC) as described previously \[[@CR18], [@CR19], [@CR21]\]. During \[ATP\]~M~ measurements, cells were superfused with HEPES/Tris medium containing 5 μM beetle luciferin (Promega, Madison, WI). Prior to \[Ca^2+^\]~M~ measurements, mtAEQ was reconstituted with 5 μM native coelenterazine (Promega) in serum-free M199 medium for 1 h at 37°C. The wild-type aequorin-native coelenterazine pair measures Ca^2+^ concentrations in the 0.1--10 µM range and mtAEQ photon emission was converted off-line to Ca^2+^ concentration by using of a computer algorithm based on the Ca^2+^ response curve of wild-type aequorin \[[@CR28]\]. Bk was added through the superfusion medium.

Fluorescence imaging of \[Ca^2+^\]~C~ {#Sec6}
-------------------------------------

\[Ca^2+^\]~C~ was measured by digital imaging microscopy of fibroblasts loaded with fura-2 as previously described \[[@CR18], [@CR19], [@CR21]\]. Bk, applied through the superfusion medium, evoked a transient increase in fura-2 fluorescence emission ratio. The rate of Ca^2+^ removal was determined by fitting the decay phase of the transient to a mono-exponential equation as described before \[[@CR18], [@CR19], [@CR21]\].

Determination of ER~Ca~ {#Sec7}
-----------------------

ER~Ca~ was determined by digital imaging microscopy of fibroblasts loaded with fura-2 as described before \[[@CR18], [@CR19], [@CR21]\]. Briefly, cells were challenged with 2′,5′-di(*tert*-butyl)-1,4-benzohydroquinone (BHQ; 10 µM), a specific inhibitor of the ER Ca^2+^ ATPase, in the absence of external Ca^2+^ (no Ca^2+^ added to the extracellular medium and in the presence of 0.5 mM EGTA). Under these conditions, Ca^2+^ that passively leaks out of the ER is not resequestered, resulting in a rapid increase in \[Ca^2+^\]~C~. The peak increase in fluorescence emission ratio after treatment with BHQ was used as a measure of ER~Ca~.

Chemicals and statistics {#Sec8}
------------------------

Culture material and TMRM were from Invitrogen (Breda, The Netherlands). Trolox was from Fluka (Buchs, Switzerland). All other reagents were from Sigma (Zwijndrecht, the Netherlands). Values from multiple experiments were expressed as average ± S.E.M and statistical significances were assessed by Student\'s *t*-test.

Results {#Sec9}
=======

**∆*ψ* is reduced in complex-I-deficient patient fibroblasts** Using our recently developed method for microscopic quantification of ∆*ψ* in cultured human skin fibroblasts \[[@CR13], [@CR27], [@CR29]\], we here show that ∆*ψ* is variably decreased in fibroblast lines of ten complex-I-deficient patients compared to four healthy individuals (Fig. [1](#Fig1){ref-type="fig"}a). For each cell line, the average TMRM intensity per mitochondrial pixel is expressed relative to that of C-5120 healthy fibroblasts measured on the same day. Linear regression analysis revealed the absence of any correlation between ∆*ψ* and residual complex I activity. Fig. 1Mitochondrial membrane potential is reduced in complex-I-deficient patient fibroblasts and correlates with cellular ROS levels and ER Ca^2+^ content. **a** Mean TMRM pixel intensity in healthy and complex-I-deficient human skin fibroblasts. In each experiment, the mean value obtained with healthy control fibroblasts (C-5120) was set at 100%, to which all values were related. Significant differences with C-5120 are indicated by \**p* \< 0.05 and \*\*\**p* \< 0.001. *Error bars* indicate SEM. *Numerals within bars* indicate the number of individual cells analyzed. **b** Linear relationship between mean TMRM pixel intensity and cellular reactive oxygen species (ROS) levels, indicated by the rate of oxidative formation of fluorescent 5-(and -6)-chloromethyl-2′,7′-dichlorofluorescein (CM-DCF), for fibroblast lines of three healthy subjects (C-5120, C-5118, C-5119; closed circles) and ten patients (S7-5175, S2-5170, S8-6603, S1-6173, S2-5737, V1-5171, V1-5866, S4-4608, S4-5260, S2-5067; open circles). **c** Linear relationship between mean TMRM pixel intensity and endoplasmic reticulum Ca^2+^ content (ER~Ca~). CM-DCF and ER~Ca~ data were taken from \[[@CR19], [@CR20], [@CR23], [@CR31]\]

**∆*ψ* is related to cellular ROS levels and ER~Ca~** We showed previously that cellular ROS levels are elevated to a variable extent in our whole cohort of complex-I-deficient patients (Table [1](#Tab1){ref-type="table"}; \[[@CR22], [@CR23]\]). Linear regression analysis revealed a negative correlation between ROS levels and ∆*ψ* (Fig. [1](#Fig1){ref-type="fig"}b). We have also shown that, similar to cellular ROS levels, ER~Ca~ is variably decreased in these patient fibroblasts (Table [1](#Tab1){ref-type="table"}; \[[@CR19]\]). Again a significant, this time positive correlation was observed (Fig. [1](#Fig1){ref-type="fig"}c).

**Chronic Trolox treatment normalizes ∆*ψ*** Based on the significant correlation between ROS levels and ∆*ψ*, as shown in Fig. [1](#Fig1){ref-type="fig"}b, we concluded that lowering of oxidant levels may restore the electrochemical proton gradient across the inner mitochondrial membrane. We previously demonstrated that chronic treatment of patient fibroblasts with Trolox, a water-soluble analogue of vitamin E, reduced ROS levels and increased the amount of fully assembled complex I \[[@CR30]\]. Figure [2](#Fig2){ref-type="fig"} shows that chronic Trolox (300 µM, 72 h) fully restored ∆*ψ* in S4-5260 and S7-5175 patient cells, which were among those displaying the largest decrease in ∆*ψ* (Fig. [1](#Fig1){ref-type="fig"}a). Trolox did not affect ∆*ψ* in healthy fibroblasts. Fig. 2Trolox treatment restores the mitochondrial membrane potential in complex-I-deficient patient fibroblasts. Mean TMRM pixel intensity in healthy (C-5120; *black bars*) and patient (S4-5260, S7-5175; *open bars*) fibroblasts cultured for 72 h in the absence or presence of Trolox (300 µM). In each experiment, the mean value obtained with vehicle-treated healthy fibroblasts was set at 100%, to which all values were related. (*a*) Significantly different from vehicle-treated C-5120. (*b*) Significantly different from vehicle-treated S4-5260. (*c*) Significantly different from vehicle-treated S7-5175. The values presented are the mean ± SEM of 100--200 individual cells. (\*\*\**p* \< 0.001)

**Chronic Trolox treatment dose-dependently increases ER~Ca~** A reduced ∆*ψ* may have severe consequences for mitochondrial energy metabolism and thus for cellular processes, such as ER Ca^2+^ uptake, that depend hereupon. This prompted us to investigate the possibility that Trolox may restore ER~Ca~ in our patient fibroblasts. Indeed, chronic Trolox (72 h) dose-dependently increased ER~Ca~ to ∼135% of the value obtained with untreated C-5120 healthy cells in both these and S4-5260 patient fibroblasts (Fig. [3](#Fig3){ref-type="fig"}). The half-maximal effect was reached at ∼85 µM Trolox. In sharp contrast, acute application of Trolox (500 µM; 30 min) neither changed ER~Ca~ in healthy (*n* = 22 cells) nor increased it in patient (*n* = 21 cells) fibroblasts (data not shown). The S4-5260 patient cell line was selected because it was among those with the largest decrease in ∆*ψ* and ER~Ca~. Fig. 3Trolox treatment dose-dependently increases the ER Ca^2+^ content in complex-I-deficient patient fibroblasts and healthy fibroblasts. Endoplasmic reticulum Ca^2+^ content (ER~Ca~) in healthy (C-5120; *open bars*) and patient (S4-5260; *black bars*) fibroblasts cultured for 72 h in the absence or presence of the indicated concentration of Trolox. For each experimental condition, the values presented are the average ± SEM of 20--50 fibroblasts. (*a*) Significantly different from vehicle-treated healthy fibroblasts. (*b*) Significantly different from corresponding vehicle-treated patient fibroblasts (\*\*\**p* \< 0.001)

**Chronic Trolox treatment restores aberrant Ca^2+^ and ATP handling during bradykinin stimulation** In a final series of experiments, we assessed the effect of chronic Trolox on the Bk-induced increase in \[Ca^2+^\]~C~, the ensuing increases in \[Ca^2+^\]~M~ and \[ATP\]~M~ and the rate of cytosolic Ca^2+^ removal. Figure [4](#Fig4){ref-type="fig"}a shows that chronic Trolox dose-dependently increased the amplitude of the Bk (1 µM)-induced increase in \[Ca^2+^\]~C~ to ∼125% of that in untreated C-5120 healthy cells in both these and S4-5260 patient cells. The half-time of Ca^2+^ removal (*t*~1/2~) decreased from 22.5 ± 0.8 s (*n* = 28 cells) and 14.6 ± 0.6 s (*n* = 28 cells) for untreated and Trolox-treated patient fibroblasts, respectively. This means that Trolox also normalized the slower cytosolic Ca^2+^ removal rate in patient cells. Trolox did not alter *t*~1/2~ in healthy fibroblasts (*t*~1/2~ = 14.2 ± 0.8 s and 14.5 ± 0.6 s for 24 untreated and 31 Trolox-treated healthy cells, respectively). Fig. 4Trolox treatment restores Ca^2+^ and ATP handling in patient fibroblasts. **a** Dose-dependence of the effect of Trolox treatment for 72 h on the Bk-induced increase in \[Ca^2+^\]~C~ in healthy (C-5120; *closed bars*) and patient (S4-5260; *open bars*) fibroblasts. **b** The same for \[Ca^2+^\]~M~ and **c** the same for \[ATP\]~M~. The values presented are the mean ± SEM of 20--30 cells (**a**) or five to 15 coverslips (**b** and **c**). For each parameter, the mean value obtained with vehicle-treated healthy fibroblasts was set at 100%, to which all values were related. (*a*) Significantly different from vehicle-treated C-5120. (*b*) Significantly different from corresponding vehicle-treated S4-5260 (\*\*\**p* \< 0.001)Chronic Trolox did not affect the Bk-induced peak increase in \[Ca^2+^\]~M~ in healthy fibroblasts (Fig. [4](#Fig4){ref-type="fig"}b). In S4-5260 patient cells, however, chronic Trolox dose-dependently increased this parameter to the same value as in untreated healthy cells. Chronic Trolox was also without affect on the Bk-induced peak \[ATP\]~M~ increase in healthy cells, whereas it normalized this parameter in patient cells (Fig. [4](#Fig4){ref-type="fig"}c).

Discussion {#Sec10}
==========

NADH:ubiquinone oxidoreductase or complex I forms a major entry point of electrons into the mitochondrial OXPHOS system and its malfunction is associated with a wide variety of clinical presentations \[[@CR2]\]. To understand the cellular mechanisms underlying these syndromes, we study cultured skin fibroblasts of a unique cohort of patients with inherited complex I deficiency of nuclear origin \[[@CR20], [@CR31], [@CR32]\]. One of our most striking findings is that the amount of fully assembled complex I is markedly decreased in patient fibroblasts, indicating that in addition to a likely decrease in intrinsic catalytic activity also its assembly and/or stability is compromised \[[@CR22], [@CR30], [@CR32]\]. Other important findings include increased ROS levels and disturbances of Ca^2+^ and ATP homeostasis both at rest and during stimulation \[[@CR20], [@CR31]\]. It is presently unknown how these changes are exactly brought about in these patient fibroblasts.

Here, we show that ∆*ψ* is significantly reduced in our cohort of patient fibroblast lines. At first glance, the most likely explanation would be a decrease in proton translocation. However, the OXPHOS system is most probably not working at its maximum capacity in resting fibroblasts and may, therefore, very well be able to maintain ∆*ψ* even when the maximum capacity of its first complex is decreased due to a lower expression and/or decreased intrinsic catalytic activity. Given the strong correlation between ROS levels and ∆*ψ*, i.e., the higher these levels, the less negative ∆*ψ*, the above finding could also be explained in that increased ROS levels induce a proton leak \[[@CR33]\]. The relevance of the consequent ∆*ψ* decrease would be to try and prevent excessive ROS production. We also show that ∆*ψ* and ER~Ca~ are correlated, i.e., the less negative ∆*ψ*, the lower ER~Ca~. Because ∆*ψ* is an important determinant for the rate of mitochondrial ATP production, this result is in agreement with our idea that fueling of ER Ca^2+^-pumps with mitochondrial ATP is reduced in resting patient fibroblasts. Importantly, our previous results argue against the idea that the reduction in ER~Ca~ is due to increased ROS-induced Ca^2+^ leak \[[@CR18]\].

The other major finding is that chronic Trolox normalizes ∆*ψ* in patient fibroblasts without affecting this parameter in healthy cells. This result is consistent with the above-described mechanism in which elevated ROS levels cause an increase in mitochondrial proton leak. Additional support comes from work demonstrating that Trolox is an efficient inhibitor of such a proton leak \[[@CR34]\]. Normalization of ∆*ψ* likely restores cellular processes that are disturbed by its disease-associated reduction. Among these processes, adequate delivery of mitochondrial ATP to ER Ca^2+^-pumps is of crucial relevance. Strikingly, chronic Trolox increased ER~Ca~ in both healthy and patient fibroblasts. Although the increase in healthy cells was unexpected in view of the lack of effect of chronic Trolox on ∆*ψ*, it should be noted that the increase in ER~Ca~ observed with 100 µM Trolox was much more pronounced in patient cells, suggesting a dual mechanism involving normalization of ∆*ψ* (only in patient cells) and modification of a hitherto unknown process (both in healthy and patient cells). Such a dual mechanism is consistent with the idea that elevated ROS levels hamper proper fueling of ER Ca^2+^-pumps primarily by their effect on ∆*ψ*. Future research will reveal whether the ∆*ψ*-independent mechanism involves a decrease in passive Ca^2+^ leak, an increase in Ca^2+^ buffering capacity in the lumen of the ER and/or an increase in glycolytic ATP-dependent Ca^2+^ uptake.

The present result that the effect of chronic Trolox on ER~Ca~ was paralleled by a similar effect on the Bk-induced increase in \[Ca^2+^\]~C~ is consistent with the linear relationship between both parameters in our cohort of patient fibroblast lines \[[@CR19]\]. Similar to our finding, Trolox enhanced the bombesin-induced increase in \[Ca^2+^\]~C~ in skin fibroblasts of patients with genetic and non-genetic forms of Alzheimer\'s disease \[[@CR35]\]. Although chronic Trolox markedly enhanced the Bk-induced increase in \[Ca^2+^\]~C~ in both healthy and patient fibroblasts, it did not affect the consequent increase in \[Ca^2+^\]~M~ in healthy cells, whereas it dose-dependently normalized this parameter in patient cells. Calibration of the mtAEQ signal revealed that Bk increased \[Ca^2+^\]~M~ to ∼4.5 µM \[[@CR18], [@CR19], [@CR21]\], whereas the maximum Ca^2+^ concentration that can be measured is 10 µM \[[@CR28]\]. Therefore, the results obtained suggest that the capacity of mitochondria to take up Ca^2+^ is restricted to a maximum that is reached with 1 µM Bk and cannot be exceeded even when the Bk-induced increase in \[Ca^2+^\]~C~ is further increased by the action of Trolox. Additional evidence for restricted Ca^2+^ uptake capacity was obtained in experiments with an inhibitor of mitochondrial Na^+^--Ca^2+^ exchange. As expected, this inhibitor, CGP-37157, did not alter the Bk-induced increase in \[Ca^2+^\]~C~, whereas it normalized the Bk-induced increase in \[Ca^2+^\]~M~ in patient cells \[[@CR18], [@CR21]\]. Strikingly, CGP-37157 was without effect in healthy control cells, which is in agreement with the idea that 1 µM Bk maximally increases \[Ca^2+^\]~M~ in healthy fibroblasts.

In agreement with the widely accepted notion that hormone-induced increases in \[Ca^2+^\]~M~ stimulate mitochondrial ATP production \[[@CR20]\], we show that chronic Trolox can normalize this process in patient fibroblasts without affecting it in healthy fibroblasts. Chronic Trolox normalized the rate of cytosolic Ca^2+^ removal during the decay phase of the Bk-induced \[Ca^2+^\]~C~ transient in patient fibroblasts without affecting this parameter in healthy cells. The same observation was reached using CGP-37157 \[[@CR18], [@CR21]\], whereas the opposite was observed with the mitochondrial Ca^2+^ buffer Rhod-2 \[[@CR21]\]. These results, together with the fact that the Bk-induced increase in \[ATP\]~M~ is tightly correlated with the rate of cytosolic Ca^2+^ removal for the whole cohort of patient fibroblasts \[[@CR19]\], clearly link these two processes.

In conclusion, the present results support the idea that fueling with mitochondrial ATP of cytosolic processes that are stimulated by hormone-induced increases in \[Ca^2+^\]~C~, such as exocytotic release of neurotransmitters in nerve cells and contraction and relaxation of muscle cells, may be hampered in complex I deficiency. It is these two cell types that are among the most vulnerable in this disease \[[@CR2]\]. However, the most important conclusion of this study is that the aberrations in Ca^2+^-stimulated mitochondrial ATP production and the consequences thereof, such as observed in complex I deficiency, can be overcome with drugs that normalize the stimulus-induced increase in \[Ca^2+^\]~M~ by either blocking mitochondrial Ca^2+^ export (CGP-37157) or increasing mitochondrial Ca^2+^ uptake (Trolox). It remains an important future task to translate this cellular information to clinical practice. Because patients with inborn errors of mitochondrial metabolism present with variable disease onset and a broad range of clinical symptoms, disease-adapted or even individualized treatment strategies might be required. In this context, Trolox and CGP-37157 constitute interesting new candidates to be evaluated as treatment options.
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Δ*ψ*

:   mitochondrial membrane potential

Bk

:   bradykinin

CI

:   complex I or NADH:ubiquinone oxidoreductase

OXPHOS

:   oxidative phosphorylation

ROS

:   reactive oxygen species

TMRM

:   tetramethyl rhodamine methyl ester

ER

:   endoplasmic reticulum

ER~Ca~

:   ER total Ca^2+^ content

\[Ca^2+^\]~C~ and \[Ca^2+^\]~M~

:   cytosolic and mitochondrial free Ca^2+^ concentration

\[ATP\]~M~

:   mitochondrial ATP concentration
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